Stock Analiz

iHuman Inc. IH

Other Consumer Services · IPO 2020 · data as of November 13, 2026

$0.99Market cap $51M
Open the interactive analysis →

iHuman Inc. (IH) is a real estate company listed in the US with a market value of about $51M. In fiscal year 2025 it had revenue of $115M and net income of $14M, a net margin of 11.8%.

Its overall Stock Analiz score is 2.4 out of 5 (weak). The strongest part is financial health (5/5); the weakest is track record (0/5).

Key numbers: a P/E of 3.7, a price to free cash flow of 7.6, 5-year revenue growth of 7% a year, a 5-year average ROIC of 6%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 74% above the current price.

About iHuman

iHuman is listed in the US and classified in other consumer services, IPO year 2020. Revenue went from $82M in 2020 to $115M in 2025, growth of about 7.2% a year. It was profitable in 4 of the last 6 years in our data. It spends 26% of revenue on research and development.

Score: 2.4 / 5

Value4/5
Future growth1/5
Track record0/5
Financial health5/5
Shareholder returns2/5

Checks passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Positive free cash flow
  • Interest covered more than 5 times

Checks not passed

  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving
  • 3-year free cash flow growth above 10% a year
  • 5-year EPS growth above 10% a year
  • 5-year revenue growth above 8% a year
  • 5-year average ROIC above 12%

Valuation

P/E (TTM)3.7
Forward P/E—
P/FCF7.6
P/S0.4
P/B0.4
EV/EBITDA-10.5
PEG—
Dividend yield11.05%
FCF yield13.1%
Shareholder yield15.9%
Intrinsic value vs. price+74%

Growth and quality

Revenue growth (1 yr)-8.7%
Revenue growth (5 yrs, per year)7.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)-36.9%
Net margin (5-yr avg.)9.5%
ROIC (5-yr avg.)6.2%
Profitable years (of last 10)4
Years paying a dividend2

Financials, last 6 years

Fiscal year202520242023202220212020
Revenue$115M$126M$143M$143M$148M$82M
Net income$14M$14M$25M$16M-$6M-$6M
Free cash flow$7M$7M$23M$26M$930000$32M
EPS (diluted)$0.27$0.26$0.50$0.31$-0.11$-0.11
Net margin11.8%10.7%17.8%11.1%-3.9%-7.0%
ROIC6.2%6.6%14.8%11.9%-8.4%-5.4%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

What is iHuman’s P/E ratio?

About 3.7, based on the last twelve months of diluted earnings per share.

Is iHuman stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 74% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does iHuman pay a dividend?

Yes. The dividend yield is about 11.05%, and it has paid dividends for 2 years in our data.

Is iHuman a good stock to buy?

We do not give buy or sell advice. iHuman scores 2.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.